251 related articles for article (PubMed ID: 29113986)
1. Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial.
Paller CJ; Zhou XC; Heath EI; Taplin ME; Mayer T; Stein MN; Bubley GJ; Pili R; Hudson T; Kakarla R; Abbas MM; Anders NM; Dowling D; King S; Bruns AB; Wagner WD; Drake CG; Antonarakis ES; Eisenberger MA; Denmeade SR; Rudek MA; Rosner GL; Carducci MA
Clin Cancer Res; 2018 Jan; 24(2):306-315. PubMed ID: 29113986
[No Abstract] [Full Text] [Related]
2. A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination.
Paller CJ; Rudek MA; Zhou XC; Wagner WD; Hudson TS; Anders N; Hammers HJ; Dowling D; King S; Antonarakis ES; Drake CG; Eisenberger MA; Denmeade SR; Rosner GL; Carducci MA
Prostate; 2015 Oct; 75(14):1518-25. PubMed ID: 26012728
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer.
Pantuck AJ; Pettaway CA; Dreicer R; Corman J; Katz A; Ho A; Aronson W; Clark W; Simmons G; Heber D
Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):242-8. PubMed ID: 26169045
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer.
Paller CJ; Ye X; Wozniak PJ; Gillespie BK; Sieber PR; Greengold RH; Stockton BR; Hertzman BL; Efros MD; Roper RP; Liker HR; Carducci MA
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):50-5. PubMed ID: 22689129
[TBL] [Abstract][Full Text] [Related]
5. A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer.
Lin J; Zahurak M; Beer TM; Ryan CJ; Wilding G; Mathew P; Morris M; Callahan JA; Gordon G; Reich SD; Carducci MA; Antonarakis ES
Urol Oncol; 2013 Jul; 31(5):581-8. PubMed ID: 21816640
[TBL] [Abstract][Full Text] [Related]
6. The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer.
Paller CJ; Olatoye D; Xie S; Zhou X; Denmeade SR; Eisenberger MA; Antonarakis ES; Carducci MA; Rosner GL
Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):28-33. PubMed ID: 24100642
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
8. A Placebo-Controlled Double-Blinded Randomized Pilot Study of Combination Phytotherapy in Biochemically Recurrent Prostate Cancer.
van Die MD; Williams SG; Emery J; Bone KM; Taylor JM; Lusk E; Pirotta MV
Prostate; 2017 May; 77(7):765-775. PubMed ID: 28181675
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2).
Freedland SJ; Allen J; Jarman A; Oyekunle T; Armstrong AJ; Moul JW; Sandler HM; Posadas E; Levin D; Wiggins E; Howard LE; Wu Y; Lin PH
Clin Cancer Res; 2020 Jun; 26(12):3035-3043. PubMed ID: 32108029
[TBL] [Abstract][Full Text] [Related]
10. A review of pomegranate in prostate cancer.
Paller CJ; Pantuck A; Carducci MA
Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):265-270. PubMed ID: 28440320
[TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.
Smith MR; Manola J; Kaufman DS; George D; Oh WK; Mueller E; Slovin S; Spiegelman B; Small E; Kantoff PW
Cancer; 2004 Oct; 101(7):1569-74. PubMed ID: 15468186
[TBL] [Abstract][Full Text] [Related]
12. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
13. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S
Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740
[TBL] [Abstract][Full Text] [Related]
14. Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial.
Antonarakis ES; Kibel AS; Yu EY; Karsh LI; Elfiky A; Shore ND; Vogelzang NJ; Corman JM; Millard FE; Maher JC; Chang NN; DeVries T; Sheikh NA; Drake CG;
Clin Cancer Res; 2017 May; 23(10):2451-2459. PubMed ID: 27836866
[No Abstract] [Full Text] [Related]
15. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
Shulman MJ; Karam JA; Benaim EA
Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
[TBL] [Abstract][Full Text] [Related]
16. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.
Valicenti RK; DeSilvio M; Hanks GE; Porter A; Brereton H; Rosenthal SA; Shipley WU; Sandler HM;
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1064-71. PubMed ID: 16979837
[TBL] [Abstract][Full Text] [Related]
17. Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy.
Pinover WH; Horwitz EM; Hanlon AL; Uzzo RG; Hanks GE
Cancer; 2003 Feb; 97(4):1127-33. PubMed ID: 12569615
[TBL] [Abstract][Full Text] [Related]
18. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time.
Kollmeier MA; McBride S; Taggar A; Anderson E; Lin M; Pei X; Weiji S; Voros L; Cohen G; Yamada Y; Zelefsky MJ
Brachytherapy; 2017; 16(6):1091-1098. PubMed ID: 28838648
[TBL] [Abstract][Full Text] [Related]
19. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.
Smith MR; Manola J; Kaufman DS; Oh WK; Bubley GJ; Kantoff PW
J Clin Oncol; 2006 Jun; 24(18):2723-8. PubMed ID: 16782912
[TBL] [Abstract][Full Text] [Related]
20. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
